ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2308

The Prevalence of Comorbidities in Pediatric Psoriasis and Juvenile Psoriatic Arthritis

Cuoghi Edens1, Angela Byun Robinson2 and Maria Antonelli3, 1Division of Pediatric Infectious Diseases and Rheumatology and Division of Rheumatology, Rainbow Babies and Children's Hospital and University Hospitals Cleveland Medical Center, Cleveland, OH, 2Division of Pediatric Infectious Diseases and Rheumatology, Case Western Reserve University School of Medicine, Rainbow Babies and Children’s Hospital, Cleveland, OH, 3Department of Medicine/Division of Rheumatology, Case Western Reserve University School of Medicine, MetroHealth Medical Center, Cleveland, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Diabetes, hypertension, obesity, pediatric rheumatology and psoriatic arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 7, 2017

Session Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Adult-onset psoriasis (PsO) and psoriatic arthritis (PsA) have been associated with increased rates of diabetes, obesity, and hypertension.  We sought to evaluate the prevalence of these comorbidities in children with PsO and juvenile PsA (JPsA) in the United States. 

 

Methods:

Utilizing a secure cloud-based platform, Explorys, we conducted a retrospective cross-sectional study of males and females ≤ 19 years of age from the United States with PsO and JPsA using pooled de-identified data from multiple United States healthcare systems, collected from 1999 to 2017. PsO subjects carried this diagnosis and also met exclusion criteria for any inflammatory arthritis or inflammatory bowel disease (IBD).  Patients with both IBD and JPsA were included and analyzed separately.  Comorbidities of interest included diabetes, hypertension, and obesity.  Hypertension and diabetes was determined by the presence of their respective Systematized Nomenclature for Medicine-Clinical Terms (SNOMED-CT), as the Explorys database is ontology based.   Subjects were considered obese if body mass index (BMI) was equal to or greater than the 95th percentile, based on CDC 2010 recommendations.  Chi-squared test and odds ratio were calculated using Stata 10.0 software, Austin, Texas.   

Results:

Of those ≤19 years of age, 6180 subjects with PsO were identified and 930 were identified with JPsA, 50 of those were also diagnosed with IBD. Of the PsO subjects, 54% were male versus 34% of total JPsA.  Both cohorts were mostly Caucasian, with over three-fourths representation.  Among children with PsO, 42% were obese compared to 52% of JPsA children.  In this cohort, those with JPsA and IBD did not have concomitant diabetes or hypertension.  JPsA patients were significantly more likely to have diabetes, hypertension, and obese than patients with purely skin disease.  Having JPsA was associated with diabetes (OR 0.33, 0.23-0.48), hypertension (OR 0.41, 0.30-0.51), and obesity (OR 0.75, 0.65-0.86) compared to PsO.  Table 1 summarizes the findings of each patient population at the time of data collection. 

Conclusion:

Metabolic comorbidities are more prevalent in children with JPsA than PsO.  Hypertension and diabetes diagnosed in childhood is more common in those with JPsA compared to those with skin disease only.  Those diagnosed with PsO and JPsA in childhood have high rates of obesity, when determined by BMI percentile. 

 

Table 1. Comorbidities in Pediatric Psoriasis and Juvenile Psoriatic Arthritis

 

PsO

N=6180

N (%)

JPsA+IBD

N=50

N (%)

JPsA-IBD

N=880

N (%)

Total JPsA

N=930

N (%)

JPsA+IBD v JPsA-IBD

p value

PsO v Total JPsA

p value

PsO v Total JPsA

OR (95% CI)

Diabetes

90 (1.5)

0 (0)

40 (4.5)

40 (4.3)

–

p< 0.0001

0.33 (0.23-0.48)

Hypertension

170 (2.6)

0 (0)

60 (6.8)

60 (6.5)

–

p< 0.0001

0.41 (0.30-0.56)

Obese*

2490 (41.0)

40 (80.0)

440 (50.0)

480 (51.6)

<0.0001

p< 0.0005

0.75 (0.65-0.86)

Legend-Psoriasis (PsO),  Juvenile Psoriatic arthritis (JPsA), Inflammatory bowel disease (IBD)

*Obese state determined as those ≥95th BMI percentile for age

 

 

 


Disclosure: C. Edens, None; A. Byun Robinson, None; M. Antonelli, None.

To cite this abstract in AMA style:

Edens C, Byun Robinson A, Antonelli M. The Prevalence of Comorbidities in Pediatric Psoriasis and Juvenile Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-prevalence-of-comorbidities-in-pediatric-psoriasis-and-juvenile-psoriatic-arthritis/. Accessed March 8, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-comorbidities-in-pediatric-psoriasis-and-juvenile-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.